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Campylobacter jejuni is a leading cause of bacterial-derived gastroenteritis 
worldwide. In the developed world, campylobacteriosis is most commonly 
acquired following the consumption of cross contaminated foods or undercooked 
poultry meat, since the bacterium asymptomatically colonizes chickens. In the 
developing world, infection most commonly occurs through drinking 
contaminated water. Following ingestion, Campylobacter adheres to the intestinal 
epithelium and mucus layer, causing toxin-mediated inflammation and inhibition 
of fluid reabsorption. Currently, the bacterial mechanisms behind colonization 
and disease are relatively unknown. Thus, it is important to identify factors that 
influence the development of these sequelae during and after initial C. jejuni 
infection.  
Ferrets (Mustela putorius furo) have been previously used as an animal 
model of human campylobacteriosis, but intensive investigation into this model 
has yet to be performed. Thus, in this study, we non-invasively examined for 
disease in ferrets and determined whether there were any effects on 
development following infection with C. jejuni. Ferrets were effectively colonized 
by C. jejuni with peak fecal loads observed at day 3 post-infection, and with full 
resolution by day 12 post-infection. Infected male ferrets had reduced weight 
when compared to uninfected males early in infection, but this was resolved by 
the conclusion of the experiment. All infected ferrets exhibited reduced activity 
and minor changes in fecal consistency. Cytokine levels in serum increased in 
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response to infection, with significance observed for IL-10 and TNF? (tumor 
necrosis factor alpha). Occult blood was observed in both uninfected and 
infected cohorts. Additionally, in response to infection, the neutrophil protein 
calgranulin C (S100A12) was found to be increased in the feces of both ferrets 
and humans infected with C. jejuni, while calprotectin (another neutrophil protein) 
was not. The addition of either purified S100A12 or of calprotectin to in vitro 
cultures of C. jejuni was found to inhibit growth in a zinc-dependent manner. 
These results suggest that upon infection with C. jejuni, neutrophils that are 
trafficked to the intestine release S100A12 and possibly calprotectin as a 
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CHAPTER ONE  




Campylobacter is a Gram-negative, rod-shaped member of the group 
Epsilonproteobacteria, and is closely related to Helicobacter. It is a motile 
organism that typically has either a single polar flagellum or bipolar flagella and 
moves in a corkscrew fashion (Fonseca, Fernández, & Rossi, 2016). 
Campylobacter is a microaerophile that grows preferentially between 37?C and 
42?C (Penner, 1988). Although this bacterium cannot grow in vitro at 
temperatures below 37?C, it is able to survive and perform basic metabolic 
functions at temperatures as low as 4?C (Hazeleger et al., 1998). This explains 
how some Campylobacter species can survive on stored poultry meat for 
extended periods of time and resume proper function once ingested. Several 
Campylobacter species reside asymptomatically in the gastrointestinal tract of 
chickens and other domestic livestock. Chickens become colonized early in life 
(approximately 2-3 weeks after hatching) and are typically colonized for life 
(Sahin et al., 2013). 
Some thermotolerant species of Campylobacter, such as C. jejuni, C. coli, 
and C. lari, can infect humans and cause bacterial gastroenteritis (Penner, 1988). 
C. jejuni and C. coli are the most common causes of Campylobacter infection. 
Campylobacteriosis typically produces symptoms such as acute mild to severe 
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watery or bloody diarrhea, fever, and abdominal pain. Symptoms last 
approximately one week and the onset of symptoms occurs 24 to 72 hours 
following ingestion (Man, 2011). In developing countries, infection most 
commonly occurs through drinking contaminated water. Children five years of 
age and younger are particularly susceptible to infection, which may lead to 
persistent colonization in the gastrointestinal tracts of these children. Although 
campylobacteriosis symptoms do not tend to last much longer, this persistence 
can cause further complications such as stunting (Amour et al., 2016). In the 
developed world, Campylobacter infection is most commonly acquired through 
the consumption of contaminated meat, and young adults (15-24 years old) as 
well as children are susceptible to infection (Friedman et al., 2000). 
Campylobacter is typically self-limiting in immunocompetent patients, but 
can lead to more serious diseases and higher instances of death in those 
persistently colonized, people with compromised immune systems, young 
children, and the elderly (Amour et al., 2016; Coker et al., 2002). Complications 
such as Guillian-Barré syndrome, septicemia, reactive arthritis, and Miller Fisher 
syndrome can occur following campylobacteriosis (Goldstein et al., 2016). 
Campylobacter has also been linked to certain irritable bowel diseases such as 
ulcerative colitis and Crohn’s disease (Kaakoush et al., 2014). Studies have 
shown that up to 80% of all fresh broiler chicken meat is contaminated with 
Campylobacter (EFSA, 2014). The estimated cost of campylobacteriosis and 
resulting complications is approximately $1.7 billion annually in the United States 
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alone (Maue et al., 2014). The high cost, serious complications, and ease of 
infection of Campylobacter makes it a priority to study. 
C. jejuni 
Campylobacter jejuni accounts for approximately 90% of all 
campylobacteriosis cases (Gillespie et al., 2002). This bacterial species alone is 
the most common cause of food-borne bacterial-derived gastroenteritis in the 
world and it is estimated that as much as 80% of all poultry carcasses in the 
European Union are contaminated with C. jejuni (European Food Safety 
Authority, 2010). Previously, it was thought that C. jejuni colonizes chickens 
without causing any physiological signs of illness (Hermans et al., 2012). 
However, a more recent study shows that C. jejuni colonization in broilers does 
provoke an inflammatory immune response, and that the level of inflammation 
stays elevated in certain breeds. This was seen by the elevated levels of the 
proinflammatory cytokines CXCLi1, CXCLi2, and IL-1?. Additionally, the authors 
of this study found increased incidences of diarrhea in chickens colonized by C. 
jejuni, which may be linked to skin disorders found in these birds, such as 
pododermatitis, as well as damage to the intestinal mucosa (Humphrey et al., 
2014). 
Under harsh environmental conditions, such as in aquatic environments or 
on abiotic surfaces, C. jejuni is able to form biofilms (Maal-Bared et al., 2012). 
Aerobic and low nutrient environments promote the formation of these biofilms 
(Reeser et al., 2007; Reuter et al., 2010). Although the mechanism of C. jejuni 
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biofilm formation is unknown, studies have shown that this ability requires 
quorum sensing, functioning flagella and certain surface proteins (Asakura et al., 
2007; Reeser et al., 2007). Studies have also shown that when in a biofilm, C. 
jejuni changes the regulation of certain genes. More specifically, it has been 
shown that iron uptake is upregulated, as well as proteins that are used for 
oxidative defense and membrane transport (Sampathkumar et al., 2006). 
Campylobacter biofilm formation may hint at a method of preventing C. jejuni 
infection in humans, as different strains of C. jejuni have been seen to have 
varying levels of ability to form biofilms due to mutations in either a putative 
flagellar protein or a phosphate acetyltransferase (Joshua et al., 2006). 
C. coli 
While Campylobacter jejuni is responsible for approximately 90% of all 
campylobacteriosis cases worldwide, C. coli accounts for approximately 10% of 
all cases (Gillespie et al., 2002). C. jejuni is typically the most abundant species 
of Campylobacter present in chickens and cattle (Thakur et al., 2006). However, 
C. coli has been shown to be more prevalent in broiler meat than C. jejuni in 
some countries (European Food Safety Authority, 2010; Torralbo et al., 2015). 
Additionally, C. coli is known to be more prevalent in pigs than C. jejuni (Thakur 
et al., 2006). Increasingly, incidences of C. coli are becoming more prevalent. 
One study reports that C. coli may be responsible for as high as 25% of all 
Campylobacter-related enterocolitis (Man, 2011). C. jejuni and C. coli share 
many of the same pathological symptoms. A recent case study has even shown 
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evidence for C. coli’s ability to cause the rare campylobacteriosis complication 
myopericarditis (Moffatt, Moloi, & Kennedy, 2017). Fortunately, serious 
campylobacteriosis complications such as myopericarditis rarely cause 
prolonged damage or death (Imazio et al., 2014). It is speculated that such 
complications are caused by excessive antibiotic treatment of 
campylobacteriosis, as antibiotics are commonly used as a treatment for 
Campylobacter infection, since there is no standard for how long antibiotics 
should be given or at what dosage (Hessulf et al., 2016). 
Other Strains 
Although C. jejuni and C. coli are the main causes of campylobacteriosis, 
other Campylobacter strains have been shown to cause disease (Meunier et al., 
2016b). For instance, C. concisus is a strain of Campylobacter often found in 
human oral cavities of both diseased and healthy individuals (Zhang et al., 2010; 
Peterson et al., 2007). Although harmless to the oral cavitiy, C. concisus has 
been linked to triggering inflammatory bowel disease (Zhang et al., 2014). 
Similarly, C. rectus can be found in the human oral cavity. However, this 
Campylobacter species is known to cause periodontitis as well as gastrointestinal 
symptoms (Mahlen & Clarridge, 2009). C. rectus may also lead to complications 
such as Crohn’s disease and ulcerative colitis (Mukhopadhya et al., 2011; Man et 
al., 2010), and has been seen to cause severe acute otitis media under certain 
circumstances (Kakuta et al., 2016). C. fetus, a strain often found in cattle and 
sheep, produces the typical gastrointestinal symptoms associated with 
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campylobacteriosis in humans as well as systemic infections in rare cases 
(Wagenaar et al., 2014). Certain subspecies of C. fetus may also cause 
spontaneous abortion both in humans and in cattle (Fujihara et al., 2006; Mshelia 
et al., 2010). C. curvus is a relatively new Campylobacter species that is rarely 
found in humans, but when present may cause severe diarrhea (Abbott et al., 
2005). Additionally, in a more recent study, C. curvus was present in a vaginal 
infection and may have contributed to premature birth (Mendz et al., 2014). 
Campylobacter lari is another species that is rarely isolated from humans, but is 
known to cause enteritis, bacteremia, and urinary tract infections (Bézian et al., 
1990). C. lari has also been seen to infect prosthetics, and such an infection 
resulted in the death of an immunocompetent patient (Werno et al., 2002). 
   
Campylobacter Mechanism of Infection 
 
Little is known about how Campylobacter is able to successfully infect 
humans and colonize chickens. C. jejuni, the most prevalent Campylobacter 
species, typically resides in the cecal mucosal crypts of colonized birds (Coward 
et al., 2008). Campylobacter counts as high as 108 CFU (colony forming 
units)/gram of cecal contents has been isolated from chicken cecal mucosa 
(Meade et al., 2009). Although it is generally accepted that this colonization has 
no effect on birds, evidence has recently suggested that Campylobacter does 
indeed promote an immune response in these animals, and that this response 
can be damaging to the intestines (Humphrey et al., 2014). Many efforts to 
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control or reduce Campylobacter loads in broiler farms have proven to be 
ineffective, perhaps in part due to the lack of knowledge of how this bacterium is 
spread to chickens. Several studies have demonstrated that Campylobacter is 
highly unlikely to be spread from breeder hens to eggs, either due to the difficulty 
of this pathogen infecting the chick or the lack of similarity in the genotypes of C. 
jejuni isolated from breeder hens compared to those later isolated from broilers 
(Jacobs-Reitsma, 1995; Sahin, Kobalka, & Zhang, 2003; O’Mahoney et al., 2011; 
Patriarchi et al., 2011). Instead, it has been shown that Campylobacter is able to 
survive outside of a host for an extended period of time, and that it is more likely 
that chicks are colonized when exposed to C. jejuni in the environment (Murphey, 
Carroll, & Jordan, 2006; Newell, 2002; Sahin, Morishita, & Zhang, 2002). 
 The most common mode of transmission of Campylobacter to humans in 
the developed world is through the consumption of undercooked poultry meat, 
which typically becomes contaminated during the slaughtering process when C. 
jejuni from the intestines comes into contact with the meat (Friedman et al., 2000; 
Humphrey, O’Brien, & Madsen, 2007). Once ingested, Campylobacter must 
invade the intestinal mucosa and adhere to intestinal epithelial cells. When the 
submucosa and nearby tissues are reached, bacteria are able to reach essential 
nutrients such as iron, and peristaltic forces no longer reach the bacteria, making 
it drastically easier to stay attached to the host. How Campylobacter is able to 
reach this area of the intestines is still a mystery, but it is known that flagellum, 
serine protease HtrA, and lipooligosaccharide play a role in C. jejuni invasion 
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(Backert et al., 2013). Once Campylobacter has managed to adhere to the 
intestinal epithelium, it induces diarrhea in its host. This increases its spread 
throughout the host intestines as well as to new hosts (Young, Davis, & Dirita, 
2007; van Putten et al., 2009; Dasti et al., 2010). 
Antibiotic Resistance in Campylobacter 
    
Campylobacter antibiotic resistance is on the rise, with resistance to 
fluoroquinolone antimicrobials such as ciprofloxacin being reported most 
frequently in several countries (Engberg et al., 2001; Moore et al., 2006; 
Alfredson & Korolik, 2007). In the United States and Canada, ciprofloxacin 
resistance is estimated to be around 19-47% (Gaudreau & Gilbert, 2003; Gupta 
et al., 2004; Nachamkin, Ung, & Li, 2002), while in Europe ciprofloxacin 
resistance is widespread and may be as high as 99% in human and animal 
isolates (Alfredson & Korolik, 2007; Papavasileiou et al., 2007; Gallay et al., 
2007; Hakanen et al., 2003; Krausse & Ullmann, 2003). A more recent study 
confirms the accuracy of these estimates, stating that ciprofloxacin resistance in 
human Campylobacter isolates is around 23% in Montreal, and does indeed 
appear to be rising (Gaudreau et al., 2014). Investigations in Germany, Ireland, 
and Italy have yielded similar results (Luber et al., 2003; Lucey et al., 2002; 
Pezzotti et al., 2003). In Africa and Asia, fluoroquinolone-resistant 
Campylobacter was not found before 1991, but is now highly prevalent, with 
resistance rates over 80% in some parts of Thailand and Hong Kong (Isenbarger 
et al., 2002; Putnam et al., 2003; Tjaniadi et al., 2003; Chu et al., 2004). 
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Fluoroquinolone resistance in Australia and New Zealand is much lower than in 
other countries, but is still present at low rates (around 3%). However, this is 
typically associated with Campylobacter infection acquired during travel. This 
lack of resistance is likely due to it being unlawful to distribute fluoroquinolones to 
food animals in Australia (Unicomb et al., 2003). 
 In addition to fluoroquinolone resistance, some Campylobacter strains 
have acquired resistance to macrolides, but this appears to depend greatly on 
the strain as well as the animal from which it was isolated (Belanger & Shyrock, 
2007). For instance, in North America erythromycin (the most commonly used 
macrolide against Campylobacter) resistance is normally around 10%. However, 
in C. coli found in turkeys and pigs in the same regions, erythromycin resistance 
was around 40% on average, with some instances of up to 80% (Luangtongkum 
et al., 2006; Thakur & Gebreyes, 2005). Similarly, throughout Europe macrolide 
resistance is low in Campylobacter, except for C. coli isolated from chickens and 
pigs, which has resistance rates up to 80% (Papavasileiou et al., 2007; McGill et 
al., 2006; Bardon et al., 2008; Gibreel & Taylor, 2006). In Asia and Australia, as 
in previously mentioned countries, macrolide resistance is mostly found in C. coli 
isolated from pigs (Miflin, Templeton, & Blackall 2007; Hong et al., 2007; Senok 
et al., 2007; Shin & Lee, 2007). In Africa, interestingly, erythromycin resistant 
Campylobacter is more commonly isolated from humans than from any food 




 Although the major antibiotics used against Campylobacter are 
erythromycin and ciprofloxacin, it is important to note that many strains of 
Campylobacter have been found to be resistant to additional antibiotics that are 
less often used for this type of infection. Resistance to tetracycline in broilers is 
seen to change with age. One study reported that Campylobacter isolated from 
broilers 3-4 weeks old was not resistant to tetracycline, while 66.7% of isolates 
from 5-week-old chicks were resistant and 100% of isolates from chicks 6-7 
weeks old were resistant. Resistance prevalence then decreases and levels off 
around 10-15% in mature chickens (Luangtongkum et al., 2008). This may be 
due to the initial time Campylobacter is attempting to colonize, followed by a 
spike, where the maximum amount of Campylobacter is present (and thus the 
maximum amount of gene transfer can occur), and then a leveling off. 
Tetracycline resistance is widespread and reported at relatively high numbers-
46% in Finland (Hakanen et al., 2003), 37.8% in Germany (Luber et al., 2003), 
and 43-68% in Canada (Gaudreau & Gilbert, 2003). Similar to erythromycin 
resistance, streptomycin resistance appears to be most prevalent in C. coli 
strains isolated from pigs, and is not as prevalent as other antimicrobial 
resistances (Pezzotti et al., 2003; McGill et al., 2006). Ampicillin resistances in 
Campylobacter isolates have also been reported in several countries, but 
prevalence appears to vary greatly from country to country-17% in Finland 
(Hakanen et al., 2003), approximately 50% in France (Gallay et al., 2007), and 
31% in the United States (Luangtongkum et al., 2008). C. jejuni shows a higher 
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incidence of resistance than other Campylobacter strains (McGill et al., 2006). 
Like most of the discussed antibiotic resistances, Campylobacter ampicillin 
resistance is rising, particularly in human isolates (Luber et al., 2003). 
Mechanisms of Antimicrobial Resistance 
In Campylobacter, antimicrobial resistance can be gained either through 
mutations or through horizontal gene transfer. Fluoroquinolone resistance in 
Campylobacter is acquired via specific point mutations in DNA gyrase A, in what 
is known as the “quinolone resistance-determining region” (Payot et al., 2006). 
Other bacterial species such as Salmonella and Escherichia coli must have 
multiple point mutations in DNA gyrase A to gain fluoroquinolone resistance, but 
Campylobacter loses susceptibility to this antibiotic after just a single point 
mutation (Luo et al., 2003). Macrolide resistance is more difficult for 
Campylobacter to attain as it requires modification of a ribosomal target. 
Resistance can occur via a point mutation in 23rRNA or in the L4 and L22 
ribosomal proteins. Resistance can alternatively occur through enzyme-mediated 
methylation of these sites (Gibreel & Taylor, 2006; Payot et al., 2006). However, 
gaining macrolide resistance through ribosomal point mutations is far more 
common, and only C. rectus is known to gain resistance via methylation (Roe, 
Weinberg, & Roberts, 1995; Luangtongkum et al., 2009; Concoran et al., 2006). 
 Not all Campylobacter antibiotic resistance occurs via mutations. For 
example, tetracycline resistance is conferred through the gene tet(O), which 
encodes a ribosomal protection protein (Taylor et al., 1985). This is the only gene 
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in Campylobacter that is known to provide tetracycline resistance. The tet(O) 
gene is common among various Campylobacter species and is present in 
isolates from many different animals (Moore et al., 2006). This gene is thought to 
have initially been acquired via horizontal gene transfer from either 
Streptomyces, Streptococcus, or Enterococcus (Batchelor et al., 2004; Taylor, 
Garner, & Allan, 1983). Campylobacter is highly resistant to beta-lactam 
antibiotics due to its ability to produce beta-lactamase (Zhang & Plummer, 2008), 
and also has intrinsic resistance to a variety of antibiotics such as bacitracin, 
trimethoprim, and vancomycin (Taylor & Courvalin, 1988; Corry et al., 1995). 
Additional Complications of Antibiotic Resistance 
 Antibiotic resistance in Campylobacter is becoming increasingly common, 
making infections more difficult to treat. This resistance is probably due to 
overuse of antibiotic treatments during Campylobacter infection, with no standard 
dosage or length of treatment (Hessulf et al., 2016). Antibiotic resistance can 
spread easily, even between different Campylobacter strains, via horizontal gene 
transfer either in bacterial cultures (Jeon et al., 2008; Wilson et al., 2003) or in 
chicken intestines (Avrain, Vernozy-Rozand, & Kempf, 2004; Boer et al., 2002). 
Campylobacter effectively carries out conjugation at not only an intraspecies 
level (Pratt & Korolik, 2005; Avrain, Vernozy-Rozand, & Kempf, 2004), but at an 
interspecies and occasionally even an intergenous level (Gibreel, Skold, & 
Taylor, 2004; Nirdnoy, Mason & Guerry, 2005). Many of the plasmids that 
Campylobacter typically transfers via conjugation carry genes that confer 
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resistance to tetracyclines and aminoglycosides (Pratt & Korolik, 2005; Gibreel, 
Skold, & Taylor, 2004). Antibiotic resistance in bacteria is often associated with a 
fitness cost such as a reduced growth rate in antibiotic-free environments 
(Luangtongkum et al., 2009). This does appear to be the case with lower levels 
of erythromycin resistance in Campylobacter (Caldwell, Wang, & Lin, 2008). 
However, it has been demonstrated that fluoroquinolone resistance in 
Campylobacter is not only stable in the absence of antibiotics, but that 
fluoroquinolone-resistant mutants actually have enhanced fitness as they are 
able to effectively outcompete other strains in a chicken host (Luo et al., 2005). 
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The CDC and WHO have classified Campylobacter as a serious threat to 
public health due to the high number of reported infections each year, the 
seriousness of both the infection and post-infectious complications, and 
Campylobacter’s resistance to the clinically-important antibiotics ciprofloxacin 
and azithromycin (Johnson, Shank, & Johnson, 2017). Because of this, it is 
important to understand how Campylobacter affects its host and it is necessary 
to consider non-antibiotic methods of treatment for this pathogen. One promising 
solution is S100 proteins, which are commonly used as markers of 
gastrointestinal inflammation (Leach et al., 2007). Some S100 proteins, such as 
S100A12 (calgranulin C) and S100A8/S100A9 (calprotectin), are known to have 
antimicrobial properties (Kehl-Fie & Skaar, 2010).  
S100 proteins are regulators of several important cell processes in 
vertebrates including energy metabolism, growth, motility, cell cycle regulation, 
apoptosis, transcription, proliferation, differentiation, and inflammation. These 
proteins are absent in invertebrates. There are currently around 20 different 
known S100 proteins, all with the ability to bind calcium (Heizmann, Fritz, & 
Schäfer, 2002; Donato et al., 2013). S100 proteins are named for their solubility 
in 100% ammonium sulfate saturated solution at a neutral pH. They are small 
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(10-12 kilodaltons), acidic proteins that are classified by their two distinct EF-
hand calcium-binding regions (Sedaghat & Notopoulos, 2008). Binding calcium 
allows them to regulate numerous intracellular and extracellular processes and 
signaling pathways. In this way, they are physiologically necessary to keep 
excess calcium out of certain pathways and to prevent the precipitation of 
calcium (Donato et al., 2013). S100 proteins are typically activated by a specific 
molecule such as a growth factor, cytokines, or toll-like receptor ligands. They 
can be secreted from the cell, where they act as damage-associated molecular 
pattern factors (DAMPs) or alarmins. Secreted S100 proteins help to regulate 
innate and adaptive immune responses as well as cancer cell locomotion and 
tissue repair under certain circumstances (Donato, 2007; Ehrchen et al., 2009; 
Hsu et al., 2009; Sorci et al., 2011). 
Each S100 protein has its own set of intracellular functions that are 
upregulated and downregulated individually. These functions are often necessary 
for proper cell function, but are extremely unrelated (Table 1). For example, 
S100A1 is mainly expressed in skeletal muscle fibers, cardiomyocytes, and 
neurons (Donato, 2001) and is important for the contractile function of these 
muscles (Rohde et al., 2010), while S100A2 binds p53 proteins (proteins 
responsible for regulating cell growth and proliferation), and thus is recognized as 
a tumor-suppressing protein (van Dieck et al., 2009). S100 proteins have gained 
increasing amounts of attention due to many of them, like S100A2, being 
involved in cancer regulation. However, it is important to note that other S100  
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Table 1. Summary of S100 proteins. Each protein has an individual intracellular and extracellular 
function that may or may not be related to one another and to the functions of other S100 proteins 
(Donato et al., 2013). 
Protein Intracellular Function Extracellular Function 
S100A1 Muscle contraction, energy Enhances Ca2+ influx 
S100A2 Tumor suppression Chemotactic for eosinophils 
S100A3 Epitehlial cell differentiation No known extracellular roles 
S100A4 Cell survival, motility, and invasion Cell migration, tumor growth 
S100A5 No known intracellular roles No known extracellular roles 
S100A6 Cell proliferation Regulates secretion 
S100A7 Tumorigenesis Innate immunity 
S100A8 Immune response Regulates inflammation 
S100A9 Inhibits monocyte differentiation Reduces inflammation 
Calprotectin Myeloid cell differentiation Neutrophil chemotaxis 
S100A10 Membrane protein trafficking Macrophage recruitment 
S100A11 Recombinational DNA damage Chondrocyte differentiation 
Calgranulin C Vascular remodeling Pro-inflammatory reactions 
S100A13 Release of fibroblast growth factor Secretion of FGF-1 
S100A14 Cancer suppressor Proliferation and apoptosis 
S100A15 No known intracellular roles Chemotactic for monocytes 
S100A16 Adipogenesis No known extracellular roles 
S100B Stimulate proliferation, inhibit Protects neuronal cells 
S100G Cytosolic Ca2+ buffer No known extracellular roles 
S100P Transendothelial migration of tumor Tumor growth and  drug 




proteins carry out equally important functions, such as S100A11, which can 
repair damage to recombinant DNA and can stimulate cell growth (Murzik et al., 
2008; Sakaguchi et al., 2008). 
S100 proteins can be secreted from the cell and are found in many human 
body fluids, such as semen, urine, saliva, and feces. Secreted S100 proteins are 
usually associated with active disease states, and some of these proteins can 
even be used as biomarkers for specific diseases (Mocellin, Zavagno, & Nitti, 
2008; Foell, Wittkowski, & Roth, 2007; Gogas et al., 2009; Gazzolo & Michetti, 
2010). S100 proteins have individual extracellular functions that may or may not 
relate to their intracellular functions, and for some of these proteins, extracellular 
function is determined by binding (Fritz et al., 2010). For example, S100A1 has 
relatively similar functions both inside and outside of the cell, as it is important 
intracellularly for muscle fibers and contraction, and extracellularly for calcium 
influx to cardiomyocytes (Rohde et al., 2010; Reppel et al., 2005). S100 proteins 
such as S100A2 has differing functions, as it is important for p53 binding 
intracellularly, but plays a role in chemotaxis extracellularly (van Dieck et al., 
2009; Komada et al., 1996). Also, varying amounts of S100 proteins are required 
to activate their target receptors, depending on the function to be performed 
(Donato, 2007). Since they can be excreted under certain circumstances, some 
S100 proteins may be used as disease markers, particularly for inflammation. 
Such markers could be useful to indicate levels of neutrophils present and 
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amount of phagocyte activation, which could indicate presence of inflammation 
and possibly disease progression (Foell et al., 2004). 
Calprotectin 
 
Calprotectin is also known as the S100A8/S100A9 heterocomplex. 
Intracellularly, S100A8 plays a role in the immune response that is not fully 
understood (Donato et al., 2013). Studies have shown that S100A8 is necessary 
for cell and/or immune function, as deleting this gene in mice is lethal as early as 
the embryonic stage. Mice embryos lacking the S100A8 protein were infiltrated 
with maternal cells prior to resorption (Passey et al., 1999). In some cells, 
S100A8 can be found in the nucleus, and this protein accounts for approximately 
20% of all neutrophil cytoplasm (Grimbaldeston et al., 2003). Macrophages take 
up S100A8 when exposed to oxidative stress, and this process is increased 
when the anti-inflammatory cytokine interleukin (IL)-10 is present (Donato et al., 
2013). Extracellularly, S100A8 helps to regulate inflammation, which it does by 
repelling neutrophils via oxidation sensitivity (Sroussi et al., 2006), and may play 
a role in maternal-fetal tolerance (Passey et al., 1999). Again, IL-10 upregulates 
S100A8 activity, as does corticosteroid (Hsu et al., 2005; Endoh et al., 2009). In 
contrast, S100A9 prevents reduction in telomerase activity that is caused by 
S100A8 intracellularly (Rosenberger et al, 2007). This protein is also able to 
inhibit dendritic cell and macrophage differentiation, and may contribute to tumor 
growth by producing intracellular reactive oxygen species (ROS) (Cheng et al., 
2008). When S100A9 is depleted, neutrophils are unable to properly respond to 
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certain chemoattractants, which can result in transendothelial cell migration (Vogl 
et al., 2007; McNeill et al., 200). Like S100A8, S100A9 repels neutrophils once it 
has been secreted. In this way, it is able to reduce inflammatory responses as 
well as reducing neutrophil migration (Sroussi, Berline, & Palefsky, 2007). Some 
evidence suggests that S100A9 may even be able to mediate the immune 
response to a certain degree controlling the amount of B7 co-stimulatory 
molecules are expressed on antigen presenting cells (Shimizu et al., 2011). 
 Certain functions performed by S100A8 and S100A9 are still performed in 
the S100A8/S100A9 heterocomplex (calprotectin), while others are not. For 
instance, intracellularly, calprotectin may play a role in myeloid cell differentiation 
through kinase activity, which is similar to the function of S100A9 (Lagasse & 
Weissman, 1992; Murano, Collart, & Huberman, 1989; Averill et al., 2011). The 
S100A8/S100A9 heterocomplex also performs functions independent from either 
S100A8 or S100A9 alone, such as intracellular transportation of unsaturated fatty 
acids and arachidonic acid (Siegenthaler et al., 1997). Extracellularly, this 
complex has been shown to be chemotactic for neutrophils (Ryckman et al., 
2003) and influential to the migration of several types of cells, such as myeloid-
derived suppressor cells and some tumor cells (Sinha et al., 2008; Hermani et 
al., 2006). This indicates that unlike S100A9, the heterocomplex promotes a pro-
inflammatory response. One study shows that calprotectin may also effect cell 
growth and induce certain types of apoptosis (Seeliger, 2003). 
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 When S100A8 and S100A9 heterodimerize into calprotectin, both proteins 
are stabilized. This stabilization results in elongation of the S100A9 C-terminal ?-
helix, which causes tetramers to form. Formation of these tetramers causes two 
high affinity zinc-binding sites to be exposed at the interface of the 
S100A8/S100A9 subunits (Korndorfer, Brueckner, & Skerra, 2007). This 
conformational change allows for metal sequestration, which is responsible for 
calprotectin’s antimicrobial properties (Kehl-Fie et al., 2011). Specifically, 
calprotectin has been shown to inhibit fungal species as well as Staphylococcus 
aureus by chelating zinc and manganese (Hsu et al, 2009; Corbin et al., 2008). It 
is also able to protect the skin from microbial invaders when produced by 
keratinocytes (Hsu et al., 2009). 
Calgranulin C 
 
S100A12, commonly referred to as calgranulin C, is an S100 protein with 
antimicrobial properties similar to calprotectin, but without a heterodimer form 
(Donato et al., 2013). S100A12 can typically be found in neutrophils, 
macrophages, and smooth muscle cells (Goyette & Geczy, 2010). Intracellularly, 
S100A12 functions to mediate between cytoskeletal elements and membranes 
(Vogl et al., 1999). Additionally, this protein binds calcium and appears to have 
calcium-dependent chaperone/anti-chaperone properties, which aid in the 
prevention of aldolase and GAPDH aggregation (Htakeyama et al., 2004). 
S100A12 expression in skin cells appears to halt growth (Hitomi et al., 1998). 
This is interesting, as S100A12 is also suspected to be involved in vascular 
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remodeling, and there is evidence that many vascular smooth muscle cell 
dysfunctions are associated with the overexpression of S100A12 (Hofmann 
Bowman et al., 2010). Additionally, S100A12 overexpression in the airways has 
the positive effect of reducing inflammation from allergies (Hofmann Bowman et 
al., 2011). 
 The extracellular functions of S100A12 are arguably more difficult to study 
than calprotectin, as rodents, the standard model for studying the functions of 
S100 proteins in vivo, do not have this protein in their genomes (Fuellen et al., 
2004; Ravasi et al., 2004). It is known, however, that extracellular S100A12 is 
chemotactic for monocytes and mast cells at low concentrations (Yan et al., 
2008), and that high levels of S100A12 can activate mast cells and IgE, 
stimulating pro-inflammatory cytokine production (Yang et al., 2007). S100A12 
can be activated by TNF?, IL-6, endotoxin, and LPS (Yang et al., 2001). In 
addition to promoting a pro-inflammatory immune reaction, this protein is 
important for fighting off parasites, as it is able to bind paramyosin which inhibits 
parasite growth and motility (Moroz et al., 2009). Like calprotectin, many of the 
functions of S100A12 are due to its ability to chelate zinc (Donato et al., 2013), 
but instead of also binding manganese, S100A12 is able to bind copper 
(Zackular, Chazin, & Skaar, 2015). 




The Role of Zinc in Campylobacter 
 
 Zinc is an important nutrient for animals, as too little leads to defects in 
immune function and too much can be toxic (Prasad et al., 2007, Costello et al., 
1997). Since the S100 proteins calprotectin and calgranulin C are known to bind 
zinc, and many microbes require zinc for growth, this zinc sequestration may be 
what is responsible for their antimicrobial properties (Donato et al., 2013). This is 
especially important in inhibiting Campylobacter, as this bacterium has its own 
zinc-binding protein (ZnuA) and has been shown to require zinc for colonization 
of the chicken gastrointestinal tract (Davis, Kakuda, & DiRita, 2009). In one 
study, the ability of a C. jejuni ?znuA mutant strain to colonize chicks was 
observed and it was shown that colonization ability, but not replication, was 
greatly reduced in this mutant. Zinc-binding proteins isolated from the chicken 
ceca were found to be responsible for inhibiting the growth of these mutants 
(Gielda & DiRita, 2012). 
 Aside from its importance for colonization and virulence, little is known 
about what specific functions zinc has in Campylobacter. In other 
microorganisms, zinc is known to act as a catalyst for multiple proteins by 
assisting in intramolecular interactions and protein folding (Si et al., 2017). Zinc 
has also been shown to stabilize protein structures and is thus likely involved in 
multiple cell functions (Berg & Shi, 1996). Not surprisingly, these roles make zinc 
important for microbial growth and morphology, with additional evidence 
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suggesting that zinc may also play a role in the regulation of certain 
transcriptional factors in these species (Moulin et al., 2016). 
Ferrets as a Model for Gastrointestinal Illness 
 
Ferrets (Mustela putorius furo) are an ideal animal model to use for 
Campylobacter infection because they are one of the few animals that produce 
clinical signs similar to symptoms in humans when infected, such as self-limiting 
diarrhea. Younger animals (approximately 6-7 weeks old) are ideal models as 
they produce more severe diarrhea upon infection (Bell & Manning, 1990). 
However, both young and adult ferrets will produce signs of disease (Burr et al., 
2005). Commonly used rodents such as rabbits and germ-free mice can be used, 
but must be genetically manipulated prior to infection (Yrios & Balish, 1986; 
Caldwell et al., 1983). Additionally, ferrets are susceptible to post-infections 
complications from Campylobacter, such as inflammatory bowel disease (IBD) 
(Burgess, 2007). However, great care must be taken when studying these 
animals, as slight dietary changes may also produce IBD symptoms (Watson et 
al., 2016). Unfortunately, aside from descriptions of gastrointestinal symptoms, 
the literature available on Campylobacter-infected ferrets is lacking, and much of 






CHAPTER THREE  




 Twelve weaning-aged ferrets (5.5-6 weeks of age), six males and six 
females, were obtained from Marshall BioResources (North Rose, N.Y.). Ferrets 
were individually housed at the Walters Life Sciences (WLS) Animal Facility at 
the University of Tennessee Knoxville. They were acclimated in the WLS animal 
facility for seven days to allow the animals to recover following transportation. 
Ferrets were fed Envigo Teklad global ferret diet and given water ad libitum 





Bacterial Cultures and Inoculation 
 
 The principal C. jejuni strain used in this study was 81-176. This strain 
was grown on Campylobacter-specific media and Gram strained to ensure purity 
of the culture. The pure culture was then streaked again on Campylobacter-
specific media and incubated at 37?C under microaerophilic conditions for 24 
hours. Six suspensions of C. jejuni 81-176 were made in 5mL phosphate-
buffered saline (PBS) and diluted to OD600 2. Ferrets were anesthetized with 
isoflurane and inoculum was administered via orogastric tubing and 12mL 
syringe. Six ferrets were infected with 5mL C. jejuni 81-176 OD600 2 in PBS 
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combined with 5mL 5% sodium bicarbonate buffer. Six ferrets were mock 
infected with 5mL PBS combined with 5mL 5% sodium bicarbonate buffer. 
Morphine was administered to each ferret approximately one hour following 
inoculation. 
 
Sample Collection and Campylobacter Enumeration 
 
Ferrets were weighed and measured once per week post-infection. Fecal 
and serum samples were collected on days 1, 3, 6, 7, 9, 12, and 14 post-
infection, followed by samples collection once per week. Three fecal samples 
were collected from each cage per time point in the morning. Approximately 
200mg of feces from one sample from each animal was immediately weighed out 
and diluted 1:100 in PBS. The remaining samples were immediately frozen at -
80?C. Diluted samples were further serially diluted in PBS to 10-8 and 100?L of 
each dilution was plated on Campylobacter-specific media. These plates were 
then incubated at 37?C in microaerophilic conditions for 48 hours before 
Campylobacter loads were determined. 
Ferrets were individually anesthetized with isoflurane prior to blood 
collection. Blood was drawn from the vena cava and was limited to 0.2% of the 
animal’s body weight for time points during days 1-14 post-infection, followed by 
1.5% of the animal’s body weight for blood draws once per week. After each 
collection, blood was allowed to clot in an upright position for at least 20 minutes. 
Samples were then centrifuged at 3500 rpm for 15 minutes. Serum was then 
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pipetted into clean 1.5mL Eppendorf tubes and frozen at -80?C. The remainder of 




Serum samples collected days 1 through 14 were analyzed at Vanderbilt 
University Medical Center (VUMC) using a Luminex mouse cytokine 1 panel. For 
this assay, a 96-well plate was washed prior to adding standards and samples. 
The appropriate matrix was then added to the wells, followed by antibody 
immobilized beads. The plate was then incubated overnight (16-18 hours) on a 
shaker at 4?C. After this incubation, plate contents were removed and the plate 
was washed three times with buffer. Detection antibody was then added to each 
well and the plate was shaken for one hour at room temperature. Following 
incubation, Streptavidin-Phycoerythrin was added to each well and the plate was 
incubated for 30 minutes at room temperature with shaking. The contents of the 
plate were removed and the plate was washed three times with buffer. After 
washing, drive fluid was added to each well and the plate was shaken at room 
temperature for five minutes. Finally, the plate was read on a MAGPIX using 
EXPONENT software and results were analyzed using Milliplex Analyst software. 
Using this method, levels of IL-1?, IL-10, IL-12p40, and TNF? were compared in 






Several assays were performed on fecal samples from the first 7 time 
points (days 1 through 14 p.i.). An occult blood test was performed using a 
Beckman Coulter Hemoccult II test kit. This procedure involved smearing a thin 
layer of feces over the specified box, incubating 3-5 minutes, applying two drops 
of Hemoccult Developer solution, and reading the result within 60 seconds. 
Results were subjectively scored using “0” as a negative, “0.5” as a weak 
positive, and “1” as a strong or regular positive, which is shown as 
presence/absence of blue coloring. Positive and negative controls were included 
on the test strips for each sample box. 
Levels of S100A12, calprotectin, and ?1-protease inhibitor were also 
analyzed in ferret fecal samples. To analyze S100A12, protease inhibitor tablets 
were dissolved in PBS (one tablet per 15mL PBS). Approximately 0.5g of each 
fecal sample was weighed out in a falcon tube and 5mL of the protease inhibitor 
mixture was added to each sample. Samples were then vortexed vigorously and 
50?L of each sample was used in a LifeSpan BioSciences, Inc. human S100A12 
ELISA kit. This same procedure was performed to measure S100A12 levels in 
Campylobacter-infected and uninfected human fecal samples as well. A similar 
procedure was used to measure levels of calprotectin in infected and uninfected 
ferret and human fecal samples, with the modification of weighing out 0.1g feces 
and adding 1mL protease inhibitor mixture. Additionally, we performed a 1:10 
dilution with our samples (in sample diluent supplied in the LifeSpan 
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BioSciences, Inc. ELISA kit) to obtain results within the range of the kit (the upper 
detection limit was 2000pg/mL). Absorbance of the samples was determined 
using a plate reader immediately following the final step of the ELISA. ELISA 
plates were read at wavelength 450nm, with 620nm as the reference wavelength. 
To measure ?1-protease inhibitor levels in ferret fecal samples, a canine (Texas 
A&M) immunoassay and a human (Biovendor) ELISA kit were used. 
 
C. jejuni Growth in the Presence of S100 Proteins in vitro 
 
Dose response assays were performed on C. jejuni wild-type strain 
DRH212 using S100A12 or calprotectin as a growth inhibitor. Concentrations of 
S100A12 and calprotectin started at 1000?g/mL and were serially diluted (1:1 in 
Helicobacter pylori media) to 15.625?g/mL to determine the minimal 
concentration necessary to inhibit C. jejuni growth. These assays were carried 
out in triplicate using Helicobacter plylori media (Brucella broth with fetal bovine 
serum and calprotectin buffer) as the growth medium. For each 
S100A12/calprotectin concentration, 100?L of diluted protein was added to 
100?L of OD600 0.5 C. jejuni in a 96-well plate. These plates were read at 600nm 




Restoration of C. jejuni Growth Following Treatment with S100 
Proteins 
 
Once minimal inhibitory concentrations of S100A12 and calprotectin 
(500?g/mL) were determined, assays were carried out with the wild-type 
DRH212 C. jejuni strain and the minimal inhibitory concentration of S100A12 or 
calprotectin. Elements known to bind to or be sequestered by S100A12 or 
calprotectin were added to the wells at a concentration of 100?M. For S100A12, 
100?L of 100?M CuCl2, CaCl2, and ZnCl2 were added to a 100?L mixture of 
OD600 0.5 DRH212 with 500?L S100A12. Plates were incubated in a 
microaerophilic environment at 37?C and read at 600nm following 24-hour and 
48-hour incubation to determine if any of these elements could restore C. jejuni 
growth in vitro following S100A12 treatment. The same procedure was used to 
examine elements that can restore C. jejuni growth in vitro following treatment 
with calprotectin. The only modification was MnCl2 was used in place of CuCl2, 
as per binding specificity of this protein. Knock-out calprotectin was also used in 
this assay to ensure that the solution itself was not responsible for the inhibition 
of C. jejuni growth. 
 
RNAseq Analysis of S100A12-Treated C. jejuni 
 
 C. jejuni (strain DRH212) was incubated overnight at 37?C on two 
separate Mueller-Hinton agar plate containing 10?g/mL trimethoprim. Two more 
DRH212 cultures were incubated in identical conditions, but these had been 
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previously treated with 500?g/mL purified S100A12. Following this incubation, all 
four samples were suspended in 40mL Mueller-Hinton broth and each was 
diluted to OD600 1. These samples were then incubated at 37?C for approximately 
six hours. Samples were then centrifuged at 4000 rpm for 10 minutes. The 
supernatant was discarded and the pellet was resuspended in 1mL Trizol. 
Samples were frozen at -80?C until RNA extraction. 
 To RNA extract, the two wild-type DRH212 and the two S100A12-treated 
DRH212 samples were first thawed on ice until they were completely melted. 
They were then incubated at room temperature for five minutes. 100?L of 
chloroform was added to each sample and samples were vortexed. Samples 
were again incubated at room temperature for five minutes, followed by 
centrifugation at 15,000 rpm for five minutes at 4?C. 700?L of 100% isopropanol 
was added to fresh Eppendorf tubes. The aqueous phase was then removed 
from each centrifuged sample and added to the respective aliquots of 
isopropanol. These were vortexed briefly and centrifuged at 15,000 rpm for 10 
minutes at 4?C. Supernatant was discarded, while the pellets were resuspended 
in 150?L of 70% isopropanol. Samples were centrifuged at 15,000 rpm for five 
minutes at 4?C. All supernatant was then removed and discarded and pellet was 
air dried for approximately 15 minutes. Finally, pellets were resuspended in 50?L 
deionized RNase-free water and frozen at -20?C. 
 Samples were DNase-treated to ensure that only RNA was present. To 
DNase-treat, 20?L DNase I 10x reaction buffer was added to 30?g of each 
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thawed RNA-extracted DRH212 sample. 8?L DNase was added to each mixture 
and they were each brought to a volume of 200?L by adding RNase-free 
deionized water. Samples were incubated in a 37?C heat block for 30 minutes, 
8?L additional DNase was added, and the incubation was repeated. Samples 
were cleaned using a Zymo RNA clean and concentrate kit. Samples were then 
PCR’d to check for the presence of DNA (indicated by bands). DNA was still 
present, so 1?L DNase and 1?L DNase I 10x reaction buffer was added to each 
sample. Samples were incubated at 37?C for 30 minutes, 1?L additional DNase 
was added to each, and the incubation was repeated. Samples were then RNA 
cleaned and PCR’d once again to check for presence of DNA. The DNase-
treatment, RNA clean, and PCR were repeated once more before samples could 
be confirmed to be purely RNA. 
 The four DNA-free samples were treated with an Illumina Ribo-Zero 
Magnetic Kit to remove rRNA. DNA libraries were then made from each RNA 
sample using a MiSeq Reagent Kit v3 and following the provided protocol. 
Samples were checked for good quality using a bioanalyzer. DNA libraries were 
labelled with individual indexes, run through a MiSeq, and results were analyzed 






CHAPTER FOUR  
RESULTS AND DISCUSSION 
Sample Collection and Campylobacter Enumeration 
 
 Campylobacter-infected ferrets did not significantly differ from uninfected 
ferrets in length or weight (Figures 1A and 1B). As expected, males were 
significantly larger and heavier than females, and lengths and weights of these 
animals increased steadily over the period of the experiment. Following oral 
challenge with C. jejuni, Campylobacter loads in infected ferrets peaked at day 3 
post infection (p.i.). C. jejuni could no longer be detected by day 12 p.i. and there 
were no clinical signs of infection by this time (Figure 2). This peak and duration 
of infection is consistent with previous studies using ferrets as a disease model 
for Campylobacter infection (Bell & Manning, 1990; Nemelka et al., 2009). Using 
our screening methods, the limit-of-detection for Campylobacter was at 2.0 X 103 
CFU/g of feces. C. jejuni could not be detected in uninfected ferret feces at any 
time point and thus are not shown. Ferrets did not have frank blood present in 
their stools at any time point. Some infected ferrets displayed mildly watery stool 






Figure 1. Effect of C. jejuni infection on growth and development of ferrets. Comparison of ferret 
weight (A) and length (B). Data was analyzed with unpaired student’s t-tests using the Holm-










































































Figure 2. C. jejuni loads in feces of infected ferrets. Immediately after collection, fecal samples 
were serially diluted (1:10) in PBS. Dilutions were then plated on Campylobacter-specific media 
and incubated 48 hours at 37?C. The horizontal bars represent the average C. jejuni loads found 
in feces of infected ferrets. 
  















We initially analyzed serum samples from days 6 and 7 (the height of 
infection) for the levels of 7 cytokines (interferon-?, IL-1?, IL-6, IL-10, IL-12p40, 
IL-12p70, and TNF?) using a Luminex mouse cytokine panel. We chose our 
samples based off a previous study looking at cytokine production during C. 
jejuni infection in human dendritic cells (Hu et al., 2006). We determined that IL-
1?, IL-10, IL-12p40, and TNF? were the most elevated from baseline, so we 
analyzed the levels of these four cytokines in serum samples from days 1-14. 
When we compared all seven sets of sera from the initial time points, we saw a 
significant increase in levels of IL-10 (an anti-inflammatory cytokine) at days 1, 3, 
9, and 12 in infected ferrets. We saw a significant increase in TNF? (a pro-
inflammatory cytokine) at days 1, 3, 6, and 7 in infected ferrets (Figure 3). There 
was no significant difference in levels of IL-1? or IL-12p40 in infected versus 
uninfected ferrets at any time point. 
Infected ferrets showed a significant increase in the levels of both IL-10 
and TNF? present in serum. A large increase in TNF? production during early 
Campylobacter infection was also seen in a previous study (Hu et al., 2006). In 
this same study, IL-10 was also shown to increase significantly, but only at the 
latest time point (48 hour). Initially, we observed that significantly higher levels of 
TNF? were produced in C. jejuni infected ferrets (days 1, 3, 6, and 7). This 
signifies an increase in intestinal inflammation early in infection, since TNF? is a 
pro-inflammatory cytokine secreted by macrophages to induce an inflammatory 
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state. In addition to its upregulation during enteric pathogen infection (such as 
Campylobacter and Salmonella), TNF? is seen to be elevated in chronic 
inflammatory disorders such as inflammatory bowel disease and rheumatoid 
arthritis (van der Veek et al., 2005). IL-10, an anti-inflammatory cytokine, has a 
relatively unknown mechanism of action, but has been seen to successfully 
inhibit inflammatory responses. Additionally, IL-10 is thought to play a role in the 
prevention of inflammatory bowel disease, as both humans and mice with 
deficient IL-10 display severe intestinal inflammation (Ip et al., 2017). IL-10 levels 
were significantly elevated in infected ferrets towards the very beginning and at 
the end of infection (days 1, 3, 9, and 12). This indicates that IL-10 is initially 
elevated to keep the TNF? levels regulated and inflammation in control. IL-10 is 
also elevated late in infection in order to reduce the immune response back to 





Figure 3. Cytokine levels in ferret serum. (A) IL-1β; (B) IL-10; (C) IL-12p40; (D) TNFα. Cytokine 
levels were measured at Vanderbilt University Medical Center using the Luminex platform and 





















































































































































Occult blood is blood in stool that is not visible to the naked eye. Occult 
blood tests were performed on all ferret fecal samples from days 1-14 using a 
Beckman Coulter Hemoccult II test kit. Tests were scored based on the presence 
of blue coloring, with “0” meaning negative (no blue present), “0.5” meaning a 
weak positive (some blue, usually more towards the edge of the sample), and “1” 
being a normal or strong positive (deep blue coloring, typically present 
throughout the entire sample spot). Although there was no significant difference 
in occult blood scores at any time point for infected versus uninfected ferrets, 
infected samples from days 1, 12, and 14 appeared to have a higher incidence of 
occult blood (Figure 4). We suspect that uninfected ferrets may have had occult 
blood in their fecal samples due to stressors and lack of dietary restriction prior to 
testing, which have been seen to play a role in the motility and amount of 
secretion of the ferret gastrointestinal tract (Johnson-Delaney, 2006). 
 Neither a canine immunoassay nor a human ELISA for ?1-protease 
inhibitor was able to find any detectable levels of this protein in any of the ferret 
fecal samples at any time point (data not shown). Amount of ?1-protease 
inhibitor in human feces was not determined. Our inability to detect an elevated 
amount of ?1-protease inhibitor in any of the ferret samples using human or 
canine antigens may be a binding specification error. However, we consider this 
to indicate that ?1-protease inhibitor levels during C. jejuni infection in humans 




Figure 4. Occult blood found in ferret feces via Hemoccult II test. A score of 1 was positive, 0.5 
was a weak positive, and 0 was a negative. There were six ferrets per group per time point. Data 
was compared using a Mann-Whitney U test with ?=0.05 (n=6). 
  






















To evaluate levels of calprotectin in ferret and human fecal samples, a 
LifeSpan BioSciences, Inc. ELISA kits for calprotectin was used. Using a Mann-
Whitney U test (p<0.05), neither C. jejuni infected ferret fecal samples at any time 
point nor C. jejuni infected human fecal samples were found to have significantly 
higher levels of calprotectin when compared to the uninfected samples (Figures 
5A and 5B). Almost all ferret fecal samples had undetectable levels of 
calprotectin, while nearly all human fecal samples appeared to have normal 
levels of calprotectin (<50?g/g). This was likely due to a lack of binding specificity 
between the ferret antigens in the fecal samples and the human antibodies in the 
ELISA kit. The lack of elevation of calprotectin in infected human samples could 
be due to the use of an ELISA kit with improper detection levels. However, 
calprotectin is known to be an inaccurate biomarker when low levels of 
inflammation are present, and may also be drastically effected by the use of 
NSAIDS (Siddiqui, Majid, & Abid, 2017). Using our methods, we cannot 
accurately model calprotectin levels of C. jejuni infected humans in ferrets. 
S100A12 levels in ferret and human fecal samples were evaluated using a 
LifeSpan BioSciences, Inc. ELISA kit for S100A12. At day 7 post-infection, 
infected ferret fecal samples were shown to have a 2-fold increase of S100A12 
present compared to uninfected ferret fecal samples (Figure 6A). This result was 
found to be significant using an unpaired two-tailed Student’s t-test with Welch’s 
correction (p<0.05). No infected ferret fecal samples from any other time points 
had significantly elevated S100A12 levels compared to uninfected fecal samples. 
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This makes sense with the Campylobacter loads we saw, as this time point 
would be just after peak infection. Using these same methods, human fecal 
samples were also found to have a statistically significant (p<0.05), 
approximately 2-fold, increase in S100A12 levels when infected with 
Campylobacter versus those uninfected (Figure 6B). Since S100A12 levels in 
ferrets reflect the 2-fold increase in infected compared to uninfected samples that 
is shown in humans, we can conclude that ferrets can be used to model the 
effects of S100A12 during C. jejuni infection in humans. This is useful as 
S100A12 is as accurate as calprotectin in identifying intestinal inflammation, but 







Figure 5. Calprotectin concentrations in fecal samples. (A) Ferrets at day 7 post-infection (n=6). 
(B) Human feces submitted to the University of Nebraska Clinical Microbiology Laboratory (UTK 










































Figure 6. S100A12 concentrations in fecal samples. (A) Ferrets at day 7 post-infection (n=6). (B) 
Human feces submitted to the University of Nebraska Clinical Microbiology Laboratory (UTK IRB-
17-03795-XM). Data was compared using an unpaired two-tailed Student’s t-test with Welch’s 







C. jejuni Growth in the Presence of S100 Proteins in vitro 
 
Both calprotectin and calgranulin c (S100A12) were able to significantly 
inhibit C. jejuni growth in vitro (Figure 7). A knock-out calprotectin mutant created 
by Dr. Steve Damo at Fisk University was used to ensure that C. jejuni growth 
was not inhibited by factors other than metal sequestration. At the highest 
concentration (1000?g/mL), the knock-out mutant was able to significantly reduce 
growth, suggesting that the suspension media may have played a role in 
inhibition. However, the knock-out mutant did not inhibit growth at any other 
concentration, while both calprotectin and calgranulin c were able to inhibit 
growth at 500?g/mL. Additionally, calprotectin could significantly inhibit C. jejuni 
growth at concentrations as low as 250?g/mL. 
Calprotectin and calgranulin c (S100A12) inhibited C. jejuni growth in vitro 
at concentrations as low as 250?g/mL and 500?g/mL, respectively. The 
resuspension media that these proteins were stored in (PBS) may have slightly 
inhibited growth, as indicated by C. jejuni growth inhibition by a knock-out 
calprotectin mutant at 1000?g/mL. However, at concentrations lower than 
1000?g/mL, no inhibition was seen in C. jejuni that was treated with the knock-
out mutant. This confirms that we are indeed seeing growth inhibition caused by 
the S100 protein treatments. Calprotectin and calgranulin c are known to have 
antimicrobial properties, possibly due to their ability to sequester necessary 





Figure 7. S100 protein inhibition of C. jejuni growth in vitro. Dose response analysis using purified 
S100A12 (calgranulin C), calprotectin, or a knock-out calprotectin mutant. C. jejuni cultures were 
treated with one of the three compounds and growth was compared to that of untreated C. jejuni 
cultures (*p<0.01, Mann-Whitney U test, n=3). 
  





























implies that the C. jejuni growth inhibition we have seen is due to the necessity of  
these elements in Campylobacter survival. 
 
Restoration of C. jejuni Growth Following Treatment with S100 
Proteins 
 
C. jejuni isolates were treated with 500?g/mL of either calprotectin or 
calgranulin c. C. jejuni was then supplemented with 100?M calcium, zinc, and 
either manganese (calprotectin-treated) or copper (calgranulin c-treated) to see if 
these compounds could restore growth (Figures 8A and 8B). Calprotectin-treated 
C. jejuni grew significantly less than C. jejuni treated with a control (PBS). 
Calcium failed to restore growth in C. jejuni. Manganese was able to restore 
growth enough to not be significantly different from the control, while C. jejuni 
treated with zinc grew significantly better than the C. jejuni treated with the 
control. Likewise, calgranulin c-treated C. jejuni grew significantly less than C. 
jejuni treated with PBS. Neither copper nor calcium was able to significantly 
restore growth. Cultures treated with zinc again grew significantly better than 
those treated with the control. These results hint at the mechanism of action for 
these S100 proteins and indicate that either calcium and copper are not 
necessary for C. jejuni growth, or that S100 proteins are not as successful at 





Figure 8. Supplementation of media for C. jejuni growth restoration following S100 protein 
treatment. (A) Supplementation of calprotectin-treated media (500?g/mL) with 100?M MnCl2, 
CaCl2, and ZnCl2. (B) Supplementation of S100A12-treated media (500?g/mL) with 100?M CuCl2, 
CaCl2, and ZnCl2. (*indicates growth significantly different from that of C. jejuni growth in PBS; 






















































RNAseq Analysis of S100A12-Treated C. jejuni 
 
 Using RNAseq, S100A12-treated and untreated C. jejuni (strain DRH212) 
cultures were analyzed for differential gene expression. Surprisingly, we did not 
see any upregulation in zinc transportation systems when comparing S100A12-
treated cultures to untreated cultures. We expected the S100A12 treatment to 
cause an increase in these systems from our hypothesis that S100A12 blocks 
zinc uptake, which was formulated from our in vitro analysis of S100A12-treated 
C. jejuni cultures. We saw 15 different upregulated systems in S100A12-treated 
cultures, with energy production and conversion most frequently upregulated 
(Figure 9A). Four different systems were downregulated in the S100A12-treated 
cultures, with translation and ribosomal structure and biogenesis accounting for 
over half of all downregulated genes (Figure 9B). However, this system also 
appears to be upregulated in treated cultures, which suggests multiple genes are 
responsible for these functions in Campylobacter, and not all of these gene 
pathways are inhibited by S100A12. Likewise, cell wall/membrane/envelope 
biogenesis was seen to be both upregulated and downregulated. This 
unexpected outcome may be due to the short treatment time of DRH212 with 
S100A12 (six hours). A longer treatment time as well as a higher S100A12 
dosage (we used the minimal inhibitory concentration of 500?g/mL) may help us 
to more accurately predict changes in gene regulation of C. jejuni that has been 
treated with S100A12. Alternatively, zinc may not be necessary throughout 
different Campylobacter growth phases. To test for this, the S100A12 treatment 
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should be repeated and gene transcription should be monitored at different time 
points across multiple different growth phases. RNA seq may not be a viable 
method to determine this, but quantitative real-time PCR could be a favorable 
alternative. Zinc transporter upregulation may be happening at a translational, 
not transcriptional, level instead. If this is the case, it would be useful to observe 
Western blots and reverse transcription PCR of S100A12-treated and untreated 
C. jejuni cultures.  
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Figure 9. Differences in gene regulation of S100A12-treated C. jejuni and untreated C. jejuni, 
analyzed using RNA seq. Levels of gene transcription were compared to levels in untreated C. 
jejuni cultures. (A) Upregulated genes (n=32). (B) Downregulated genes (n=7).  
Translation, ribosomal structure and biogenesis






CHAPTER FIVE  
CONCLUSIONS AND RECOMMENDATIONS 
 Campylobacter is a leading cause of bacterial-derived gastroenteritis 
worldwide, costing approximately $1.7 billion annually in the United States alone 
(Johnson, Shank, & Johnson, 2017). In the developed world, campylobacteriosis 
is most commonly acquired through the consumption of contaminated poultry 
meat (Johnson et al., 2015). Little is known about how Campylobacter is able to 
successfully invade and colonize its hosts, though it typically resides in cecal 
mucosal crypts (Coward et al., 2008). Campylobacteriosis is a serious concern, 
as it can lead to several severe post-infectious complications such as Guillain-
Barré syndrome, septicemia, reactive arthritis, and inflammatory bowel diseases 
(Goldstein et al., 2016; Kaakoush et al., 2014). Additionally, antibiotic-resistant 
Campylobacter prevalence has been steadily increasing around the world 
(Engberg et al., 2001; Moore et al., 2006; Alfredson & Korolik, 2007), which is 
likely due to the overuse of antibiotics (Hessulf et al., 2016). 
 A possible non-antibiotic Campylobacter treatment involves the use of 
S100 proteins, particularly calprotectin (S100A8/S100A9) and calgranulin C 
(S100A12). These proteins are used as biomarkers to detect the presence of 
inflammation, as they are commonly secreted from neutrophils (Leach et al., 
2007). Additionally, these proteins are known to have antimicrobial properties 
(Kehl-Fie & Skaar, 2010). This may be due to their ability to bind calcium and to 




 We decided to observe levels of S100 proteins both in vitro and in vivo to 
determine their possible effects on Campylobacter jejuni. For our in vivo studies 
we used ferrets as a model for human infection due to their being one of the only 
animals to produce similar clinical signs to humans following infection with 
Campylobacter (Bell & Manning, 1990). We did not observe any noticeable 
differences in the sizes of infected versus uninfected ferrets. We observed peak 
Campylobacter loads at three days post-infection. We saw a significant increase 
in the levels of IL-10 at the beginning and end of infection, and in TNF? at the 
initial time points following infection. This indicates a strong pro-inflammatory 
immune response caused by TNF?, while IL-10, an anti-inflammatory cytokine, 
was likely regulating the immune reaction. There was no significant increase in 
occult blood between infected versus uninfected ferrets, but this could be due to 
the sensitivity of the ferret digestive tract (Watson et al., 2016). Finally, we did not 
observe a significant increase in calprotectin, but we did see significantly 
elevated levels of calgranulin C in infected ferrets at peak infection. This 
indicates that ferrets are a viable animal model for human campylobacteriosis 
due to their reflection of calgranulin C levels in humans during infection.  
 Our in vitro observations of the effects of calprotectin and calgranulin C on 
Campylobacter jejuni show that each of these proteins can effectively inhibit 
growth. Calgranulin C inhibits growth at concentrations as low as 500?g/mL, 
while calprotectin can inhibit growth with as little as 250?g/mL. Following this 
experiment, we supplemented back metals known to be sequestered by these 
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proteins to help determine a possible mechanism of action for Campylobacter 
inhibition. Following treatment with 500?g/mL of calgranulin C, we saw that 
100?M of zinc was able to significantly restore C. jejuni growth, while 100?M of 
calcium or copper could not. Similarly, when C. jejuni was treated with 500?g/mL 
calprotectin, 100?M of zinc was able to significantly restore growth. Additionally, 
100?M of manganese was able to restore calprotectin-treated C. jejuni growth, 
while 100?M of calcium was not. MiSeq was used to determine which genes 
were being upregulated and downregulated in response to calgranulin C 
treatment, but we did not get the results we expected, which would have shown 
us upregulation of a zinc transporter or related gene. Instead, we observed that 
the most commonly upregulated genes in calgranulin C-treated C. jejuni were 
genes involved in energy production and conversion. The most commonly 
downregulated genes were those involved in translation and ribosomal structure 
and biogenesis. A longer calgranulin C treatment time (we only incubated for 6 
hours) or a higher calgranulin C dosage (we used the minimal inhibitory 
concentration of 500?g/mL) may have produced clearer results. Alternatively, it 
would be useful to look into Campylobacter zinc regulation across multiple 
growth phases and at translational and post-translation zinc regulation. 
 In the future, it would be interesting to observe the effects of 
Campylobacter on a malnourished host and to compare the effects to those of a 
healthy host. This would be important to look at as source of infection, age 
groups commonly infected, and post-infectious complications from 
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Campylobacter differs greatly between first and third world countries. 
Campylobacter infection in third world countries is common in children five years 
old and younger and is typically acquired from contaminated drinking water 
(Johnson, Shank, & Johnson, 2017). Persistence and stunting following 
Campylobacter infection are more commonly seen in these areas of the world as 
well (Amour et al., 2016). This implies that diet plays a key role in infection and 
immune response to campylobacteriosis. We suspect that stunting may be 
caused by a lack of zinc in the host, as some S100 proteins are seen to be 
upregulated during infection and to bind zinc (Donato et al., 2013), and 
Campylobacter is also known to scavenge zinc from its host environment (Davis, 
Kakuda, & DiRita, 2009). Zinc deficiencies have been shown to lead to 
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